Now I have a thorough understanding of the paper and calibration anchors. Let me synthesize the final review.

---

## Summary

This paper proposes a framework for multi-view diabetic retinopathy (DR) grading that generates "lesion proposals" on-the-fly via a Grade-Activated Lesion Proposal (GALP) module — which uses CAMs from stage-wise auxiliary classifiers to select top-K grade-discriminative regions — and fuses them across views using a Mixture-of-Experts-based Cross-View Lesion Expert Guided Regional Fusion (LGRF) module. The method achieves competitive results on MFIDDR (83.9% without external annotations) and DRTiD (76.0%), matching or surpassing several externally-informed methods. When lesion annotations are available, performance further improves to SOTA (84.6% on MFIDDR).

## Strengths

- The paper achieves genuinely competitive results without external annotations on two multi-view DR benchmarks. On MFIDDR, "Ours (w/o lesion)" at 83.9% Acc surpasses all end-to-end baselines (e.g., MVCINN 80.1%, ETMC 81.5%) and several externally informed methods (CVSA 82.6%, LFMVDR 82.2%). On DRTiD, the method achieves 76.0% Acc, the highest overall. This demonstrates that the approach meaningfully closes the gap with annotation-dependent pipelines.

- The ablation study (Table 4) provides clear evidence that each proposed module contributes: removing GALP drops accuracy from 83.9% to 82.7%, removing the expert pool drops to 82.6%, and removing LGRF entirely drops to 82.3%. The consistent declines across all metrics confirm that the cross-view fusion architecture is genuinely beneficial.

- The LGRF module's MoE routing design — where the current view's features gate which experts process adjacent-view proposals — is a non-trivial technical contribution. The load-balancing loss (Eq. 11) and hyperparameter analysis (Fig. 3) showing stability around the chosen settings (K₂=2, M=6) add credibility to the design.

- The framework is architecturally flexible: incorporating external lesion masks via SPADE lifts accuracy to 84.6% (new SOTA on MFIDDR), demonstrating the method can benefit from additional supervision when available without structural modification.

## Weaknesses

### Fatal

None.

### Major

- **The "lesion proposal" framing is unvalidated.** The paper's central narrative is that GALP generates *lesion* proposals that can substitute for costly external lesion annotations. The only basis for calling them "lesion" proposals is the heuristic that "grade evidence in DR is predominantly localized to lesions" (Section 3.2, line 149). No empirical link between the selected top-K regions and actual retinal lesions is established. The paper provides no visual overlays of proposals on fundus images, no comparison with external lesion masks (despite MFIDDR providing them), and no localization accuracy metric. CAM-based region selection for medical images is not novel; what would distinguish this work is evidence that the selected regions correspond to clinically meaningful lesions. Without this, the method's claimed "lesion-aware" and "interpretable" properties rest on an assumption. The technical mechanism (selecting grade-discriminative regions) is valid and the performance results are real, but the "lesion" label — which permeates the paper's motivation and claimed contribution — is unsupported. This can be addressed by either (a) providing validation against lesion annotations, or (b) reframing the contribution around "grade-discriminative region proposals" without the unvalidated clinical interpretation.

### Minor

- **The ablation conflates the auxiliary loss with proposal selection.** The "w/o GALP" variant (Table 4) removes the entire GALP mechanism, which includes both the auxiliary classification loss and the Top-K token selection. There is no ablation that retains the auxiliary loss but uses all tokens (i.e., isolating the proposal selection from the auxiliary supervision). This makes it impossible to determine whether the observed gain from GALP (1.2% Acc) comes from the auxiliary supervision strengthening intermediate representations, or from the Top-K selection focusing attention on grade-relevant regions. A "w/ auxiliary loss, w/o Top-K selection" variant would disentangle these factors and strengthen the evidence for the proposal mechanism specifically.

- **The DRTiD SOTA claim rests on a narrow margin without statistical support.** The 0.4% accuracy gain over CrossFiT (76.0% vs. 75.6%) on a test set of 1,100 eyes corresponds to roughly 4–5 images. No confidence intervals, error bars, or multi-run variance is reported. While single-run evaluation is standard practice in this subfield, the claim of "highest overall accuracy" should be tempered given the margin. Similarly, on MFIDDR, several externally informed methods cluster tightly (83.0–84.6%), and without variance estimates the relative ranking among top methods is uncertain.

- **"Interpretability" and "robustness" are claimed but not evaluated.** Contribution (2) claims "superior robustness and interpretability," yet the experiments contain no interpretability analysis beyond the existence of CAM-style maps (which merely show where the model looks, not whether it looks at clinically meaningful structures), and no robustness assessment (e.g., to image quality variation, domain shift, or perturbation).

### Trivial

- The overall specificity (Spe) metric in Table 2 is not defined for the multi-class setting. It is unclear whether this is macro-averaged, micro-averaged, or computed per-class. This makes the metric difficult to interpret.

## Nice-to-Haves

- A comparison with a simpler baseline that uses the same Swin-B backbone with standard multi-head cross-attention over all tokens (no MoE, no proposal selection) would clarify whether the MoE routing and proposal selection add value beyond a simpler architecture with the same backbone and auxiliary loss.

- Qualitative visualization of what the selected top-K regions actually capture (e.g., are they vessel crossings, optic disc, exudates, microaneurysms?) would substantially strengthen the "lesion-aware" narrative or help the authors refine their claims.

## Removed Points

These points are flagged to be removed; treat them with caution.

- **Harsh Critic's claim that the central premise is "hollow" and the gap "cannot be closed by adding experiments":** This overstates the problem. The technique (CAM-based region selection) is a valid mechanism, and the performance results demonstrate that the selected regions are useful for grading. The issue is specific to the *lesion* labeling, not the technical mechanism. This can be addressed through either validation or reframing.

- **Harsh Critic's claim that the 1.2% gain from GALP is "small" and "undermines the claimed importance":** A 1.2% absolute accuracy gain is meaningful, and the consistent drops across all metrics (Acc, Spec, Kappa, F1) make it unlikely to be noise. The more precise concern — that the gain cannot be attributed to proposal selection vs. auxiliary supervision — is captured in the minor weakness above.

- **Harsh Critic's complaint about Table 1 lumping methods with different backbones:** This is standard practice in benchmarking — different papers use different architectures, and the paper transparently reports its backbone (Swin-B). The paper also follows the same pretraining conventions as prior SOTA works for each dataset. Not a valid criticism.

- **Strength Finder's claim that "self-generated lesion proposals via GALP effectively replace external annotations":** This overstates what the evidence supports. The method achieves competitive results without external annotations, but the evidence does not specifically show that the *proposals* (as opposed to the auxiliary supervision, MoE fusion, or Swin-B backbone) are what replace external annotations. The more precise claim — "the overall framework achieves competitive results without external annotations" — is accurate.

- **Strength Finder's generic strengths about the problem being "clinically relevant" and "well motivated":** These are superficial — removed.

- **Harsh Critic's note about the MoE complexity not being "argued":** The ablation ("w/o Experts" drops to 82.6%) partially justifies the MoE design. This is not a substantive weakness.

## Novel Insights

None beyond the paper's own contributions. The core idea — using CAM-based region selection to focus cross-view attention in multi-view medical image analysis — is a reasonable technical contribution, but the reviews do not surface any deeper insights about DR grading methodology that the paper itself does not already articulate.

## Suggestions

- Either validate the "lesion" label by comparing proposal regions against available lesion masks on MFIDDR (at minimum, compute overlap/IoU for a sample of images), or reframe the contribution around "grade-discriminative region proposals" without the unvalidated clinical interpretation. The latter would still be a publishable contribution given the strong results.

- Add an ablation that retains the auxiliary classification loss but uses all tokens without Top-K selection. This would cleanly separate the contribution of auxiliary supervision from that of the proposal mechanism.

- Report mean ± std from multiple runs (at least 3) for the key comparisons, particularly on DRTiD, or alternatively soften the SOTA language when margins are below 1%.

- Either add a minimal interpretability analysis (e.g., overlay proposals on fundus images for a few examples of different DR grades) or remove "interpretability" from the claimed contributions.

## Score and Decision

**Anchor comparison:**

| Path | Avg Score | Decision | Comparison to paper under review |
|------|-----------|----------|----------------------------------|
| `h2p5eOFpcF` | 5.50 | Accept (Poster) | Benchmark paper with rigorous step-level analysis; stronger validation than our paper. |
| `9gc58FeBba` | 5.00 | Reject | Multi-view DR with interpretability claims; has more conceptual/design issues, weaker results. Our paper is somewhat stronger technically. |
| `QCCMvWYwPN` | 4.50 | Reject | Dataset/benchmark paper; different genre but similar quality band. |
| `WuEE1f4NId` | 4.00 | Withdrawn | DR grading with concept learning; needs teacher model, weaker results. Our paper is stronger. |
| `K5tcKEQaUr` | 4.00 | Accept (Poster) | Retinal representation learning; clear contribution, well-validated. Our paper has more novelty but weaker validation of central claim. |
| `cESVZ0SfjA` | 1.50 | Withdrawn | Claims "theoretical framework" without theory; much weaker than our paper. |

This paper sits around the 4.5–5.0 range. It has genuine technical contributions (the MoE cross-view fusion design, competitive results without external annotations) but a significant weakness in the unvalidated "lesion proposal" framing that underpins its narrative. The issue is addressable — either through validation or reframing — but in its current form it weakens the paper's central contribution claim. The paper is stronger than the 4.0-anchored papers (more novelty, better results) but weaker than the 5.5 anchor (less rigorous validation). I place it at 5.0, comparable to `9gc58FeBba` but with cleaner technical execution and fewer conceptual problems.

MY FINAL SCORE: <pineapple>5.0</pineapple>
MY FINAL DECISION: <orange>Reject</orange>